Glen Harbor Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Glen Harbor Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$15.9M	Buy	93,742 +28,754	+44%	+$5.09M	0.33%	65
2019 Q2	$11.9M	Sell	64,988 -5,698	-8%	-$996K	0.25%	84
2019 Q1	$13M	Buy	70,686 +1,342	+2%	+$248K	0.28%	83
2018 Q4	$11.5M	Sell	69,344 -2,904	-4%	-$503K	0.28%	79
2018 Q3	$13.9M	Sell	72,248 -4,378	-6%	-$780K	0.28%	87
2018 Q2	$13M	Sell	76,626 -682	-0.9%	-$106K	0.28%	86
2018 Q1	$12.6M	Buy	77,308 +35,310	+84%	+$5.77M	0.29%	77
2017 Q4	$6.29M	Sell	41,998 -1,166	-3%	-$173K	0.14%	136
2017 Q3	$6.56M	Sell	43,164 -15,114	-26%	-$2.27M	0.16%	130
2017 Q2	$7.51M	Sell	58,278 -2,420	-4%	-$291K	0.18%	105
2017 Q1	$6.64M	Sell	60,698 -6,006	-9%	-$529K	0.17%	115
2016 Q4	$4.91M	Buy	+66,704	New	+$5.43M	0.13%	138

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glen Harbor Capital Management's VRTX Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q3 2019, buying an estimated $5.09M and bringing the position to 93,742 shares worth $15.9M. The position accounts for 0.33% of the portfolio, ranked #65.

Glen Harbor Capital Management first reported a position in VRTX in Q4 2016 and has held it in 12 quarters since. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Glen Harbor Capital Management held 93,742 shares of Vertex Pharmaceuticals worth $15.9M as of Q3 2019.
Glen Harbor Capital Management bought 28,754 Vertex Pharmaceuticals shares in Q3 2019, an estimated $5.09M.
Vertex Pharmaceuticals made up 0.33% of Glen Harbor Capital Management's portfolio in Q3 2019, its #65 holding.
Glen Harbor Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.